Order of the President of the Court of 11 April 2001. - Commission of the European Communities v Laboratoires pharmaceutiques Trenker SA. - Appeal - Order of the President of the Court of First Instance in proceedings for interim relief - Withdrawal of marketing authorisations for medicinal products for human use containing "phentermine" - Second Directive 75/319/EEC - Urgency - Balancing of interests. - Case C-459/00 P (R).



European Court reports 2001 Page I-02823



Summary

Parties

Grounds

Operative part



Keywords

1. Appeals - Pleas in law - Plea alleging incorrect appraisal of the facts - Inadmissibility - Review by the Court of Justice of the appraisal of the evidence submitted to the Court of First Instance - Possible only where the clear sense of the evidence has been distorted

(Art. 225 EC; EC Statute of the Court of Justice, Art. 51)

2. Appeals - Admissibility - Assessment in relation to the case at issue

(EC Statute of the Court of Justice, Art. 49)

3. Approximation of laws - Proprietary medicinal products - Marketing authorisation - Evaluation of the products - Assessment of their harmfulness and efficacy - Examination in relation to each other - Ongoing nature of the assessment

(Council Directives 65/65, Art. 5, and 75/318, annex)

4. Approximation of laws - Proprietary medicinal products - Marketing authorisation - Withdrawal of authorisation - Discretion of the Community authorities - Judicial review - Limits

(Council Directives 65/65, Art. 11, and 75/319, Arts 13 and 14)

Summary

1. The Court of First Instance has exclusive jurisdiction to find the facts, save where a substantive inaccuracy in its findings is attributable to the documents submitted to it, and to appraise those facts. That appraisal thus does not, save where the clear sense of the evidence has been distorted, constitute a point of law which is subject, as such, to review by the Court of Justice on appeal.

( see para. 52 )

2. The conditions governing the admissibility of appeals laid down by Article 49 of the Statute of the Court of Justice are assessed in relation to the case at issue and that alone. The fact that the grounds of an order of the Court of First Instance which has become definitive are identical to those of an order subject to appeal does not prevent the appellant from contesting such grounds.

( see para. 54 )

3. Under Article 5 of Directive 65/65 relating to proprietary medicinal products, the evaluation of every medicinal product relates to its efficacy, its harmlessness and its quality. Compliance with those three conditions is intended to protect public health. The very concept of the protection of public health means that the medicinal product in question not only must not be harmful but also must be effective. The degree of harmfulness which the competent authority may regard as acceptable thus depends on the benefits which the medicinal product is considered to provide. As stated in the seventh and eighth recitals in the preamble to Directive 75/318 relating to analytical, pharmaco-toxicological and clinical standards and protocols in respect of the testing of medicinal products, the concepts of harmfulness and therapeutic efficacy can only be examined in relation to each other. Accordingly, the reasons which have led a competent authority to preserve a marketing authorisation for a medicinal product notwithstanding certain harmful effects may cease to apply if that authority considers that the benefits justifying such an authorisation, that is to say the existence of a therapeutic effect, are no longer present. As stated in the introduction to the annex to Directive 75/318, as amended by Directive 91/507, after issue of the marketing authorisation any new data or information are to be submitted to the competent authorities in order to monitor the benefit/risk assessment.

( see paras 64, 67 )

4. Any decision withdrawing a marketing authorisation which is adopted in accordance with the procedure laid down in Articles 13 and 14 of Directive 75/319 relating to proprietary medicinal products must comply with the substantive conditions under Article 11 of Directive 65/65, which relate to the efficacy, safety and quality of the medicinal product. This type of decision is thus the outcome of complex assessments in the medico-pharmacological field. In principle, such assessments are subject to limited judicial review. Where a Community authority is called upon, in the performance of its duties, to make complex assessments, it enjoys a wide measure of discretion, the exercise of which is subject to a limited judicial review in the course of which the Community judicature may not substitute its assessment of the facts for the assessment made by the authority concerned. Thus, in such cases, the Community judicature must restrict itself to examining the accuracy of the findings of fact and law made by the authority concerned and to verifying, in particular, that the action taken by that authority is not vitiated by a manifest error or a misuse of powers and that it did not clearly exceed the bounds of its discretion.

( see paras 82-83 )

Parties

In Case C-459/00 P(R),

Commission of the European Communities, represented by H. Støvlbæk, M. Shotter and K. Fitch, acting as agents, and B. Wägenbaur, avocat, with an address for service in Luxembourg,

appellant,

supported by

French Republic, represented by G. de Bergues and R. Loosli-Surrans, acting as agents,

intervener on appeal,

APPEAL against the order of the President of the Court of First Instance of the European Communities of 19 October 2000 in Case T-141/00 R Trenker v Commission [2000] ECR I-3313, seeking to have that order set aside,

the other party to the proceedings being:

Laboratoires pharmaceutiques Trenker SA, established in Brussels (Belgium), represented by X. Leurquin and L. Defalque, avocats, with an address for service in Luxembourg,

applicant at first instance,

THE PRESIDENT OF THE COURT

after hearing Advocate General Stix-Hackl,

makes the following

Order

Grounds

1 By application lodged at the Registry of the Court of Justice on 19 December 2000, the Commission of the European Communities brought an appeal pursuant to Article 225 EC and the second paragraph of Article 50 of the EC Statute of the Court of Justice against the order made by the President of the Court of First Instance on 19 October 2000 in Case T-141/00 R Trenker v Commission [2000] ECR I-3313 (the order under appeal), by which the President of the Court of First Instance suspended operation of Commission Decision C(2000) 453 of 9 March 2000 concerning the withdrawal of marketing authorisations of medicinal products for human use which contain the following substance: amfepramone (the contested decision).

2 By document lodged at the Registry of the Court of Justice on 9 February 2001, Laboratoires pharmaceutiques Trenker SA (Trenker), the company which was the applicant at first instance, submitted its written observations to the Court of Justice.

3 By application lodged at the Registry of the Court of Justice on 29 January 2001, the French Republic sought leave to intervene in the present proceedings in support of the Commission.

4 Pursuant to the first and fourth paragraphs of Article 37 of the EC Statute of the Court of Justice and Article 93(1) and (2) of the Rules of Procedure, the application by the French Republic for leave to intervene in the present proceedings should be granted.

5 The French Republic lodged its statement in intervention on 19 February 2001.

6 The parties presented oral argument at the hearing on 7 March 2001.

Legal background

7 On 26 January 1965, the Council adopted Directive 65/65/EEC on the approximation of provisions laid down by law, regulation or administrative action relating to proprietary medicinal products (OJ, English Special Edition 1965-1966, p. 20). That directive has been amended on several occasions, in particular by Council Directive 89/341/EEC of 3 May 1989 (OJ 1989 L 142, p. 11) and Council Directive 93/39/EEC of 14 June 1993 (OJ 1993 L 214, p. 22) (Directive 65/65). Article 3 of Directive 65/65 lays down the principle that no medicinal product may be placed on the market of a Member State unless an authorisation has first been issued by the competent authorities of that Member State in accordance with the directive or an authorisation has been granted in accordance with Council Regulation (EEC) No 2309/93 of 22 July 1993 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Agency for the Evaluation of Medicinal Products (OJ 1993 L 214, p. 1).

8 Article 4 of Directive 65/65 provides in particular that, in order to obtain a marketing authorisation as provided for in Article 3, the person responsible for placing the product on the market is to apply to the competent authority of the Member State concerned.

9 Article 5 of Directive 65/65 states:

The authorisation provided for in Article 3 shall be refused if, after verification of the particulars and documents listed in Article 4, it proves that the medicinal product is harmful in the normal conditions of use, or that its therapeutic efficacy is lacking or is insufficiently substantiated by the applicant, or that its qualitative and quantitative composition is not as declared.

Authorisation shall likewise be refused if the particulars and documents submitted in support of the application do not comply with Article 4.

10 Article 10 of Directive 65/65 provides that the authorisation is valid for five years and is renewable for five-year periods after consideration by the competent authority of a dossier containing in particular details of the data on pharmacovigilance and other information relevant to the monitoring of the medicinal product.

11 The first paragraph of Article 11 of Directive 65/65 provides:

The competent authorities of the Member States shall suspend or revoke an authorisation to place a medicinal product on the market where that product proves to be harmful in the normal conditions of use, or where its therapeutic efficacy is lacking, or where its qualitative and quantitative composition is not as declared. Therapeutic efficacy is lacking when it is established that therapeutic results cannot be obtained with the [medicinal] product.

12 Under Article 21 of Directive 65/65, an authorisation to market a medicinal product may not be refused, suspended or revoked except on the grounds set out in that directive.

13 Council Directive 75/318/EEC of 20 May 1975 on the approximation of the laws of Member States relating to analytical, pharmaco-toxicological and clinical standards and protocols in respect of the testing of medicinal products (OJ 1975 L 147, p. 1), as amended by Directive 89/341 (Directive 75/318), provides, in the first paragraph of Article 1, that the Member States are to take all appropriate measures to ensure that the particulars and documents which must accompany applications for authorisation to place a medicinal product on the market pursuant to points 3, 4, 6, 7 and 8 of the second paragraph of Article 4 of Directive 65/65 are submitted by the persons concerned in accordance with the annex to Directive 75/318.

14 The seventh and eighth recitals in the preamble to Directive 75/318 are worded as follows:

... the concepts of "harmfulness" and "therapeutic efficacy" referred to in Article 5 of Directive 65/65/EEC can only be examined in relation to each other and have only a relative significance depending on the progress of scientific knowledge and the use for which the medicinal product is intended; ... the particulars and documents which must accompany an application for authorisation to place a medicinal product on the market [must] demonstrate that potential risks are outweighed by the therapeutic efficacy of the product; ... failing such demonstration, the application must be rejected;

... the evaluation of "harmfulness" and "therapeutic efficacy" may be modified in the light of new discoveries and standards and protocols must be amended periodically to take account of scientific progress.

15 The Second Council Directive (75/319/EEC) of 20 May 1975 on the approximation of provisions laid down by law, regulation or administrative action relating to proprietary medicinal products (OJ 1975 L 147, p. 13), as amended by Directive 93/39 (Directive 75/319), provides for a number of arbitration procedures before the Committee for Proprietary Medicinal Products (the CPMP) of the European Agency for the Evaluation of Medicinal Products. Such a procedure is applied where a Member State considers, in the context of the procedure for the mutual recognition of national marketing authorisations which is provided for by Article 9 of Directive 75/319, that there are grounds for supposing that the authorisation of the medicinal product concerned may present a risk to public health (Article 10 of that directive), where divergent decisions have been adopted concerning the grant, suspension or withdrawal of national authorisations (Article 11), in specific cases where the interests of the Community are involved (Article 12), and in the case of variations of harmonised authorisations (Articles 15, 15a and 15b).

16 Article 12 of Directive 75/319 provides that the Member States among others may, in specific cases where the interests of the Community are involved, refer the matter to the CPMP for the application of the procedure laid down in Article 13 before reaching a decision on a request for a marketing authorisation or on the suspension or withdrawal of an authorisation, or on any other variation to its terms which appears necessary, in particular to take account of the information collected in the context of the pharmacovigilance system provided for in Chapter Va of Directive 75/319.

17 Article 15a of Directive 75/319 states:

1. Where a Member State considers that the variation of the terms of a marketing authorisation which has been granted in accordance with the provisions of this Chapter or its suspension or withdrawal is necessary for the protection of public health, the Member State concerned shall forthwith refer the matter to the Committee for the application of the [procedures] laid down in Articles 13 and 14.

2. Without prejudice to the provisions of Article 12, in exceptional cases, where urgent action is essential to protect public health, until a definitive decision is adopted a Member State may suspend the marketing and the use of the medicinal product concerned on its territory. It shall inform the Commission and the other Member States no later than the following working day of the reasons for its action.

18 Article 13 of Directive 75/319 sets out the procedure before the CPMP. Article 14 lays down the procedure to be followed after the Commission receives the opinion of the CPMP. The third subparagraph of Article 14(1) states that where, exceptionally, the [Commission's] draft decision is not in accordance with the opinion of the Agency, the Commission shall also annex a detailed explanation of the reasons for the differences.

Facts and procedure

19 Trenker is the holder of marketing authorisations for medicinal products containing amfepramone sold under the names Dietil Retard, Regenon and Atractil. The facts of the case are set out in the order under appeal as follows:

9 On 17 May 1995 the Federal Republic of Germany made a referral to the CPMP in accordance with Article 12 of Directive 75/319, as amended by Directive 93/39, expressing its fears as regards anorectics, which include medicinal products containing amfepramone, liable to cause serious pulmonary artery hypertension.

10 The procedure initiated by this referral led to the adoption of Commission Decision C(96) 3608 of 9 December 1996 ["the decision of 9 December 1996"], based on Article 14(1) and (2) of Directive 75/319, instructing Member States to vary certain clinical information which had to appear in the national authorisations to place the medicinal products in question on the market.

11 By letter of 7 November 1997 addressed to the chairman of the CPMP, the Belgian Ministry of Social Affairs, Public Health and the Environment expressed inter alia its fears that there was a causal link between cardiac valve disorders and the use of medicinal products containing amfepramone. It therefore requested the CPMP, pursuant to Articles 13 and 15a of Directive 75/319, to issue a reasoned opinion on the medicinal products concerned.

12 On 31 August 1999 the CPMP gave its opinion on medicinal products containing amfepramone. It reached the conclusion that, although the concerns expressed by the Belgian ministry could not altogether be excluded, there was no evidence to substantiate them. However, it concluded that medicinal products containing amfepramone had an unfavourable benefit/risk balance and recommended that the marketing authorisations for those products should be withdrawn.

13 On the basis of that opinion, the Commission prepared a draft decision which was circulated in January 2000. On 9 March 2000 the Commission adopted the decision concerning the withdrawal of marketing authorisations of medicinal products for human use which contain the ... substance "amfepramone" ... Article 2 of the contested decision refers to the views expressed by the CPMP in the opinion. Article 3 provides that the Member States are to withdraw the marketing authorisations for all the medicinal products mentioned in Annex I to the contested decision within 30 days of its notification.

20 By application lodged at the Registry of the Court of First Instance on 25 May 2000, Trenker brought an action before the Court of First Instance under the fourth paragraph of Article 230 EC for annulment of the contested decision.

21 By separate document lodged at the Court Registry on 11 September 2000, Trenker made an application for suspension of operation of the contested decision.

22 Apart from the contested decision, the Commission adopted two other decisions on 9 March 2000, concerning the withdrawal of marketing authorisations for medicinal products for human use which contain phentermine (C(2000) 452) and clobenzorex, fenbutrazate, fenproporex, mazindol, mefenorex, norpseudoephedrine, phenmetrazine, phendimetrazine and propylhexedrine (C(2000) 608). All those decisions concern medicinal products for the treatment of obesity, which had already been referred to in the decision of 9 December 1996, and they were prompted by a re-evaluation of those medicinal products under Article 15a of Directive 75/319 which had been requested by two Member States. The evaluation procedure resulted in a number of opinions of the CPMP, adopted by its members almost unanimously, recommending withdrawal of the marketing authorisations for all the medicinal products for very similar reasons. The Commission decisions of 9 March 2000 are founded on those opinions.

23 Nine applications for interim relief were made in respect of the three decisions referred to in the preceding paragraph. By order of 28 June 2000 in Case T-74/00 R Artegodan v Commission [2000] ECR II-2583, the President of the Court of First Instance decided one of those applications and ordered suspension of the operation of Decision C(2000) 453 in relation to Artegodan GmbH. No appeal was brought against that order. The President of the Court of First Instance decided the other eight applications for interim relief by the order under appeal and by seven orders of 31 October 2000: in Case T-76/00 R Bruno Farmaceutici and Others v Commission [2000] ECR II-3557, Case T-83/00 R I Hänseler v Commission [2000] ECR II-3563, Case T-83/00 R II Schuck v Commission [2000] ECR II-3585, Case T-84/00 R Roussel and Roussel Diamant v Commission [2000] ECR II-3591, Case T-85/00 R Roussel and Roussel Iberica v Commission [2000] ECR II-3613, Case T-132/00 R Gerot Pharmazeutika v Commission [2000] ECR II-3635 and Case T-137/00 R Cambridge Healthcare Supplies v Commission [2000] ECR II-3653. Those eight orders, against which the Commission has brought appeals, and the order in Artegodan v Commission are founded on almost identical grounds.

The order under appeal

24 By the order under appeal, the President of the Court of First Instance granted Trenker's application for interim relief and ordered suspension of the operation of the contested decision in its regard.

25 The President of the Court of First Instance held that the condition relating to the establishment of a prima facie case was satisfied in the case in point. In this connection, he set out the following factors at paragraph 29 of the order under appeal:

29 As regards the question of a prima facie case, the pleas raised by the applicant do not prima facie appear to be entirely unfounded. First, it appears that the competence of the Commission to adopt the contested decision depends on the nature of the decision of 9 December 1996, which is open to debate. Second, the Commission has not provided any explanation, in the light of the principle of proportionality, regarding the reason for which that decision and the contested decision reached diametrically opposed results. The pleas raised by the applicant therefore deserve detailed consideration, a consideration which, however, in fact and in law, goes beyond the scope of the present interim proceedings.

26 As regards the question of urgency, the President of the Court of First Instance concluded that the damage which immediate operation of the contested decision could cause would be serious and irreparable. In reaching that conclusion, he relied on the following considerations:

36 In the present case, immediate operation of the contested decision entails the complete withdrawal from the market of the medicinal products referred to in Article 1 of the decision. It therefore also entails exclusion of those medicinal products from the pharmaceutical trade lists and their removal from the lists of medicinal products used by the medical profession as a basis for advice and prescription practice. In addition, if operation of the contested decision is not suspended, substitute medicinal products, the existence of which is acknowledged by both parties, will very probably take the place of the products withdrawn. The confidence of consumers, doctors and pharmacists in a medicinal product is particularly sensitive to statements that the product presents a danger to patients' health. Even if those statements are subsequently disproved, it is often impossible to restore confidence in the withdrawn product, other than in special cases where the qualities of the medicinal product are especially valued by users and there is no perfect substitute product, or where the manufacturer enjoys an exceptionally good reputation, so that it cannot be said that he will be unable to repossess the market shares he held before withdrawal. However, such circumstances are not present here.

37 Moreover, if the contested decision were to be annulled by the Court of First Instance and the applicant thus authorised to resume marketing its medicinal products, the financial damage suffered by it because of a fall in sales as a result of loss of confidence in its products could not in practice be quantified sufficiently completely for the purposes of making reparation.

27 The President of the Court of First Instance found that in the case in point the balance of interests favoured suspension of operation of the contested decision, on the basis of the following considerations:

42 It appears highly probable that the operation of the contested decision would entail the definitive loss of the applicant's position in the market, even if the court hearing the main application were to annul the decision.

43 Suspension of operation of the contested decision could nevertheless harm public health. On this point, it must be emphasised that in principle the requirements of the protection of public health must unquestionably be given precedence over economic considerations (order [of the Court of Justice] in [Case C-180/96 R] United Kingdom v Commission [[1996] ECR I-3903], paragraph 93; judgment in Case C-183/95 Affish v Rijksdienst Keuring Vee en Vlees [1997] ECR I-4315, paragraph 43; order of the Court of First Instance in Case T-136/95 Industria del Frio Auxiliar Conservera v Commission [1998] ECR II-3301, paragraph 58; and order of the President of the Court of First Instance in Case T-70/99 R Alpharma v Commission [1999] ECR II-2027, paragraph 152).

44 However, it must be noted that in this context the mere reference to the protection of public health cannot exclude an examination of the circumstances of the case, in particular of the relevant facts.

45 In the present case, the Commission has indeed established that there is uncertainty as regards the risks associated with medicinal products containing amfepramone, even if those risks are slight. Nevertheless, although the decision of 9 December 1996 and the contested decision are based on identical data, the measures taken by the Commission in 1996 and 2000 for the protection of public health with respect to those risks differ fundamentally. In those circumstances, the Commission was obliged to show that the protective measures in the decision of 9 December 1996 proved to be insufficient to protect public health, so that the protective measures it adopted in the contested decision were not manifestly excessive. However, the Commission has not been able to show this.

46 Moreover, the fact that the health risks which determined the adoption of the contested decision had already been taken into account in the Commission's decision of 9 December 1996 and had resulted in a change to the compulsory information concerning medicinal products supplied on prescription indicates that implementation of the contested decision is not urgent.

The appeal

Arguments of the parties

28 The Commission founds its appeal on eight pleas in law.

29 By its first plea, the Commission, supported by the French Government, complains that the President of the Court of First Instance failed to apply properly, or at all, the precautionary principle in his balancing of the interests. This principle means that the Commission may take protective measures without having to wait until the reality and seriousness of those risks become fully apparent (Case C-157/96 National Farmers' Union and Others [1998] ECR I-2211, paragraph 63).

30 The basis of the second plea is that the President of the Court of First Instance misunderstood the nature of the contested decision and the process leading to its adoption.

31 The Commission submits that, when it adopts measures to protect public health with regard to medicinal products, the scientific process of assessing risk is not undertaken by it but by scientific experts, namely the members of the CPMP. It is on the basis of that assessment that the Commission then takes its policy decision (risk management decision), weighing the result of the risk assessment with other factors to be taken into account. The lack of reference to the scientific opinion of the CPMP in the order under appeal reveals a fundamental misunderstanding of the procedure leading to the adoption of the contested decision.

32 According to the Commission, the reason why, on 9 March 2000, it adopted a decision which differed from that of 9 December 1996 is directly connected with the final opinion of the CPMP dated 31 August 1999. The Commission points out that the statement of reasons for the contested decision referred to the fact that, in the CPMP's view, medicinal products containing amfepramone lacked therapeutic efficacy in the treatment of obesity when assessed on the basis of accumulated scientific knowledge acquired over the years and current medical recommendations.

33 Between the adoption of the decision of 9 December 1996 and that of the contested decision, the guidelines concerning the therapeutic efficacy of medicinal products for the treatment of obesity and the medical guidelines on the treatment of obesity had changed, causing the CPMP to alter its scientific assessment. Those guidelines represent a fundamental change in the scientific community's assessment of how to treat obesity. By failing to take account of that fundamental factor and focusing exclusively on the identicalness of the data upon which both the abovementioned decisions are based, the President of the Court of First Instance made a material error in assessing the balance of interests. Nor is it clear from the order under appeal that the President of the Court of First Instance took account of the fact that the contested decision introduced a higher level of health protection than that resulting from the decision of 9 December 1996.

34 The French Government essentially agrees with that line of argument, submitting that the President of the Court of First Instance distorted the content of the contested decision within the meaning of the judgment in Case C-164/98 P DIR International Film and Others v Commission [2000] ECR I-447, at paragraphs 48 and 49. Such a distortion is the result of a partial reading of the decision. The President of the Court of First Instance did not take Annex II to the decision into consideration in that he failed to note that the CPMP examined additional scientific data subsequent to 1996 and omitted the fact that, according to the CPMP, the medicinal products containing amfepramone did not have the required efficacy.

35 In its third plea, the Commission complains that the order under appeal exceeds the proper boundaries of judicial review. It submits that the President of the Court of First Instance erred in law by substituting his assessment as to the appropriate level of public health protection for that of the body competent to exercise its discretion in that field, namely the Commission. The French Government essentially endorses this plea, pointing out that the Court has previously held, in Case C-120/97 Upjohn [1999] ECR I-223, at paragraphs 33 and 34, that complex assessments in the medico-pharmacological field can be subject only to limited judicial review.

36 The fourth plea alleges breach of the requirement to balance the interests involved. The President of the Court of First Instance erred in law by failing to balance properly the interests concerned, in that he examined and took into account only the economic damage to the undertaking seeking suspension of the operation of the contested decision, without taking proper account of the seriousness and the irreparable nature of harm to patients treated with the medicinal product in question. The President of the Court of First Instance did not accord to the protection of public health the precedence that is required by the Court of Justice's case-law, when the risks to human health had been established by the scientific experts on the CPMP.

37 The fifth plea concerns an error of law with regard to the standard of proof required of the Commission. The President of the Court of First Instance proceeded on the assumption that the Commission, assisted by the CPMP, is, on its own, in a position to demonstrate that a medicinal product lacks therapeutic efficacy or is harmful in the normal conditions of use. The Commission points out that the provision of data on the safety and therapeutic efficacy of a medicinal product is largely dependent on the holder of the marketing authorisation and that it is neither the Commission's nor the CPMP's role to conduct clinical trials. The approach of the President of the Court of First Instance with regard to the standard of proof would prevent the Commission from reviewing its marketing authorisation decisions unless relevant new data had arisen.

38 The sixth plea alleges material errors in relation to the finding, made in point 45 of the order under appeal, that, while there is uncertainty as regards the risks associated with medicinal products containing amfepramone, such health risks are slight. The documents submitted to the Court of First Instance clearly show that the risks associated with those medicinal products, in particular the increased risk of primary pulmonary hypertension and cardiac valve disorders, are not slight. The President of the Court of First Instance replaced the CPMP's assessment with his own.

39 The seventh plea alleges a lack of reasoning in the order under appeal with regard to the assessment by the President of the Court of First Instance that the risks associated with medicinal products containing amfepramone are slight. In the Commission's submission, no explanation is given, either in paragraph 45 or elsewhere in the order under appeal, making it possible to understand the reasons for such an assessment.

40 The eighth and last plea alleges a material inaccuracy at paragraph 29 of the order under appeal, where the President of the Court of First Instance was assessing whether a prima facie case had been made out. It is clear from the documents submitted to the Court of First Instance that the finding that the Commission had not provided any explanation, in the light of the principle of proportionality, regarding the reason for which the decision of 9 December 1996 and the contested decision reached diametrically opposed results is incorrect. The Commission refers in this regard to several passages in the contested decision and to the observations which it had submitted to the Court of First Instance in Gerot Pharmazeutika v Commission, cited above, also concerning amfepramone.

41 Trenker's primary submission is that the appeal is inadmissible.

42 First, since the Commission did not bring an appeal against the order in Artegodan v Commission, cited above, the grounds of that order should be regarded as having become definitive and as not open to challenge in an appeal concerning other cases, absolutely identical to the case which gave rise to that order. Moreover, the Commission has infringed the principle of equal treatment in appealing against only certain orders of the President of the Court of First Instance.

43 Second, the appeal is essentially founded on assessments of fact and does not demonstrate either that those assessments are substantively inaccurate or that their legal characterisation of the facts is wrong.

44 It is only in the alternative that Trenker contests the Commission's pleas for annulment of the order under appeal.

45 First, Trenker submits that the plea alleging infringement of the precautionary principle is inadmissible because such a principle was not raised before the President of the Court of First Instance and that, even if the plea is admissible, that principle has been applied only in exceptional cases, concerning emergency measures of a transitional nature. In any event, measures adopted under the precautionary principle must comply with the principle of proportionality.

46 Second, Trenker contends that the second plea relied on by the Commission is also inadmissible because it calls assessments of fact into question. As to the substance, the President of the Court of First Instance did not in any way substitute his scientific assessment for that of the Commission or the scientific experts on the CPMP. In Trenker's submission, the benefit/risk assessment of medicinal products containing amfepramone appears to be more favourable in 2000 than it did previously and, in any event, there is no new finding to justify the decision to withdraw the marketing authorisations for those products compared with the situation resulting from the decision of 9 December 1996. Trenker points out that the contested decision was not adopted for a reason relating to risk to patients' health, but solely because amfepramone allegedly lacks therapeutic efficacy. From the point of view of its harmfulness, that substance represents a minor risk, comparable to that resulting from the use of other medicinal products which continue to be sold in the European Community; furthermore, its efficacy is demonstrated by a trial taken into account by the rapporteur of the CPMP and is acknowledged in studies of a more general nature concerning anorectics.

47 Third, in Trenker's submission the President of the Court of First Instance did not exceed the proper boundaries of judicial review. However, the Commission did not establish, as required by the principle of proportionality, that the measures adopted in 1996 were insufficient to ensure that public health was protected.

48 Fourth, Trenker alleges that the Commission has radically altered its line of argument regarding the need for withdrawal of the marketing authorisations. While the Commission sought to justify that measure before the Court of First Instance by contending that amfepramone lacks therapeutic efficacy, the contested decision is explained, in the appeal, by the existence of serious heart risks for users of medicinal products containing amfepramone. Trenker contends in that regard that the CPMP concluded, so far as concerns the safety of those products, that there is no increased risk of cardiac valve disorders, and account had already been taken of the risk of primary pulmonary hypertension at the time of the adoption of the decision of 9 December 1996. It also observes that the Commission fails to take into consideration the fact that the period of validity of marketing authorisations is limited to five years and that on their renewal medicinal products are regularly re-evaluated.

49 Fifth, as regards the plea alleging a lack of reasoning in the order under appeal, Trenker submits that the order is founded on the apparent absence of Commission competence to adopt the contested decision and on infringement of the principle of proportionality and that such grounds are sufficient to enable the Court of Justice to conduct its review.

50 Finally, Trenker submits that the eighth plea is also inadmissible since it entails reconsideration by the Court of Justice of the assessment of the facts carried out by the President of the Court of First Instance. Trenker disputes the Commission's interpretation of the guidelines and considers it to be contrary to scientific truth to contend that fresh knowledge and new scientific results justified a decision as serious as that of ordering withdrawal of marketing authorisations for medicinal products containing amfepramone.

Findings

51 In accordance with Article 225 EC and Article 51 of the EC Statute of the Court of Justice, appeals are limited to points of law and lie solely on the grounds of lack of competence of the Court of First Instance, a breach of procedure before it which adversely affects the interests of the appellant or the infringement of Community law by the Court of First Instance.

52 The Court of First Instance has exclusive jurisdiction to find the facts, save where a substantive inaccuracy in its findings is attributable to the documents submitted to it, and to appraise those facts. That appraisal thus does not, save where the clear sense of the evidence has been distorted, constitute a point of law which is subject, as such, to review by the Court of Justice on appeal (see, in particular, Case C-390/95 P Antillean Rice Mills and Others v Commission [1999] ECR I-769, paragraph 29).

53 It is in the light of those considerations that the appellant's pleas should be considered.

54 First of all, in relation to the argument that the appeal is inadmissible in so far as it disregards the binding authority of the order in Artegodan v Commission, it need only be observed that the conditions governing the admissibility of appeals laid down by Article 49 of the EC Statute of the Court of Justice are assessed in relation to the case at issue and that alone. The fact that the grounds of an order of the Court of First Instance which has become definitive are identical to those of an order subject to appeal does not prevent the appellant from contesting such grounds (see, with regard to a judgment of the Court of First Instance upholding an objection of illegality raised against a legislative measure, Joined Cases C-432/98 P and C-433/98 P Council v Chvatal and Others [2000] ECR I-8535, paragraph 22).

55 As regards inadmissibility of the appeal in its entirety because it is essentially founded on assessments of fact, such a question can be considered only in the light of the arguments put forward in support of each plea challenging the order under appeal.

56 Accordingly, the appeal is admissible.

57 The plea concerning distortion of the content of the contested decision should be considered first.

58 In this connection, it is clear from the grounds of the order under appeal relating both to the establishment of a prima facie case and to the balancing of interests that the following considerations were decisive in the reasoning of the President of the Court of First Instance:

- ... the Commission has not provided any explanation, in the light of the principle of proportionality, regarding the reason for which [the decision of 9 December 1996] and the contested decision reached diametrically opposed results (paragraph 29);

- ... although the decision of 9 December 1996 and the contested decision are based on identical data, the measures taken by the Commission in 1996 and 2000 for the protection of public health with respect to those risks differ fundamentally. In those circumstances, the Commission was obliged to show that the protective measures in the decision of 9 December 1996 proved to be insufficient to protect public health, so that the protective measures it adopted in the contested decision were not manifestly excessive (paragraph 45);

- ... the health risks which determined the adoption of the contested decision had already been taken into account in the Commission's decision of 9 December 1996 and had resulted in a change to the compulsory information concerning medicinal products supplied on prescription (paragraph 46).

59 Those findings are not based on even a cursory analysis of the statement of reasons for the contested decision as set out in Annex II to the decision, to which Article 2 refers.

60 Annex II to the contested decision, which sets out the scientific conclusions of the CPMP in order to indicate the reasons leading to the withdrawal of the marketing authorisations for the medicinal products listed in Annex I to the decision, contains first of all an analysis of the efficacy of those products. It is concluded in Annex II that medicinal products containing amfepramone lack therapeutic efficacy in the treatment of obesity when assessed on the basis of accumulated scientific knowledge acquired over the years and current medical recommendations.

61 In reaching such a conclusion, Annex II states that the effect of amfepramone on weight loss is modest, never exceeding 5.1 kg whatever the treatment duration, and that the maximum effect occurred within the first one to two months and decreased immediately thereafter. With regard to the argument that a short-term lowering of body weight might be helpful within an anti-obesity programme, Annex II states that rapid weight regain occurs once treatment is discontinued and there are no controlled studies which demonstrate that a limited short-term effect has any long-term clinically relevant influence on body weight or provides a clinical benefit within an anti-obesity programme. It is also pointed out that the risk of drug abuse and drug dependence precludes that amfepramone should be used for long-term treatment. It is concluded that amfepramone has only been shown to produce modest short-term weight reductions of dubious and unproven relevance for the outcome of the disorder.

62 According to Annex II, therapeutic efficacy in treating obesity requires a significant and long-term lowering of body weight, over at least one year. It states: This is based on accumulated scientific knowledge acquired over the years and is laid down in current medical recommendations; this is reflected in the Note for Guidance on Clinical Investigation of Drugs Used in Weight Control (CPMP/EWP/281/96). This is also expressed in current guidelines, e.g. the Scottish guideline (1996), a guideline from the Royal College of Physicians (1998) and in a guideline from the American Society for Clinical Nutrition (1998).

63 The importance of those reasons given the subject-matter of the contested decision and in the light of the applicable law concerning the evaluation of medicinal products should be noted.

64 Under Article 5 of Directive 65/65, the evaluation of every medicinal product relates to its efficacy, its harmlessness and its quality. Compliance with those three conditions is intended to protect public health. The very concept of the protection of public health means that the medicinal product in question not only must not be harmful but also must be effective. As the footnotes to Article 10(1) of Directive 75/319 and Article 7a of Directive 65/65 state, the expression "risk to public health" refers to the quality, safety and efficacy of the medicinal product.

65 The importance attached to the efficacy of the medicinal product, which is fundamental to the contested decision, is due to the fact that the first subparagraph of Article 1(2) of Directive 65/65 adopts the presentation criterion when defining a medicinal product. The Court has consistently held that this criterion is designed to catch not only medicinal products having a genuine therapeutic or medical effect but also those which are not sufficiently effective or do not have the effect which their presentation might lead to expect, in order to protect consumers not only from harmful or toxic medicinal products as such but also from a variety of products used instead of the proper remedies (see, most recently, Case C-219/91 Ter Voort [1992] ECR I-5485, paragraph 16).

66 Consequently, as follows from the very wording of Article 11 of Directive 65/65, the competent authority is required to suspend or revoke a marketing authorisation not only where the medicinal product proves to be harmful or its quality not to be as declared, but also where it proves not to be effective.

67 The degree of harmfulness which the competent authority may regard as acceptable thus depends on the benefits which the medicinal product is considered to provide. As the seventh and eighth recitals in the preamble to Directive 75/318 state, the concepts of harmfulness and therapeutic efficacy can only be examined in relation to each other. Accordingly, the reasons which have led a competent authority to preserve a marketing authorisation for a medicinal product notwithstanding certain harmful effects may cease to apply if that authority considers that the benefits justifying such an authorisation, that is to say the existence of a therapeutic effect, are no longer present. It is stated in the introduction to the annex to Directive 75/318, as amended by Commission Directive 91/507/EEC of 19 July 1991 (OJ 1991 L 270, p. 32), that after issue of the marketing authorisation any new data or information are to be submitted to the competent authorities in order to monitor the benefit/risk assessment.

68 It is clear that, in its assessments regarding the establishment of a prima facie case and the balance of interests, the order under appeal makes no mention of the considerations in the statement of reasons for the contested decision relating to the change in the scientific criteria for evaluating medicinal products for the treatment of obesity and to the lack of therapeutic efficacy of medicinal products containing amfepramone.

69 In accordance with the very wording of the contested decision, such a change appears to be a decisive factor in the evaluation of those medicinal products by the CPMP and the Commission.

70 Furthermore, because of that omission, the risks to which paragraphs 45 and 46 of the order under appeal refer concern only the harmfulness of the medicinal product considered in isolation, without the harmfulness being related to the medicinal product's lack of therapeutic efficacy.

71 It follows from the foregoing that, inasmuch as the order under appeal fails to take account of essential aspects of the statement of reasons for the contested decision and, therefore, distorts the latter's content, it is vitiated by an error of law.

72 Accordingly, without it being necessary to rule on the remaining pleas, the appeal must be allowed and the order under appeal set aside.

73 In accordance with the first paragraph of Article 54 of the EC Statute of the Court of Justice, if the appeal is well founded the Court of Justice is to quash the decision of the Court of First Instance. It may then itself decide the matter directly, where the state of the proceedings so permits, or refer the case back to the Court of First Instance for judgment. Since the state of the proceedings so permits, it is appropriate to give a final decision on the application for interim relief.

The application for interim relief

Prima facie case

74 Trenker puts forward several pleas in law to establish a prima facie case for the interim relief sought.

75 First, it pleads infringement of Article 15a of Directive 75/319 and Article 11 of Directive 65/65. It submits that the Commission was not competent to adopt the contested decision. Article 15a of Directive 75/319 allows a Member State to initiate the procedure provided for in Articles 13 and 14 of that directive only in the case of marketing authorisations which have been granted in accordance with Chapter III of the directive. However, the authorisations in question are national authorisations, not authorisations granted in accordance with that chapter. The fact that they were varied by the decision of 9 December 1996, following a procedure initiated under Article 12 of Directive 75/319, does not affect that conclusion.

76 Trenker adds that Article 15a of Directive 75/319 requires the suspension or withdrawal of a marketing authorisation to be necessary for the protection of public health. However, that condition is not met because no new risk to public health has come to light since the decision of 9 December 1996. Moreover, the contested decision is founded on the alleged lack of efficacy of medicinal products containing amfepramone and not their lack of safety.

77 When the judge hearing an application for suspension of the operation of a measure assesses whether there is a prima facie case, his task is not to give a final decision on the interpretation of the provisions applicable to the dispute.

78 Subject to that proviso, it must be acknowledged that, even though the decision of 9 December 1996 did not precede the issue of the national marketing authorisations, it cannot be inferred from that circumstance that following its adoption the Member States had absolute freedom so far as concerns preservation of those national authorisations, with the risk that the harmonisation achieved by that decision would be undone. At first sight, Trenker's argument would render redundant Commission decisions concerning marketing authorisations already issued, adopted in accordance with the procedure laid down in Articles 13 and 14 of Directive 75/319.

79 In addition, it is clear from paragraph 67 of this order that, even if the referral to the CPMP was due to considerations relating to the harmfulness of medicinal products containing amfepramone, the decision which brings to an end the procedure provided for in Articles 13 and 14 of Directive 75/319 may prima facie take account of whether the benefits of those products continue to outweigh their harmful effects.

80 Accordingly, the arguments put forward by Trenker do not appear, on an initial analysis, to establish that the Commission was not competent to adopt the contested decision.

81 Second, Trenker advances a series of arguments which principally concern the discretion available to the Commission when assessing the need for a measure withdrawing a marketing authorisation. In this context, Trenker contends that the application of new standards for assessing the safety and efficacy of medicinal products containing amfepramone which have obtained marketing authorisation would result in infringement of the principles of non-retroactivity of administrative acts and of legal certainty. The CPMP failed to take account of the fact that it is impossible for the holder of a marketing authorisation to present the results of clinical tests in conformity with new guidelines, because it necessarily takes several years to carry out such tests. Trenker also submits that the requirement that the efficacy of a medicinal product for the treatment of obesity must be demonstrated over a minimum period of one year had not been adopted in 1996 and is not justified from a medical point of view. In addition, it is contrary to the principle of proportionality for the Commission, by means of the contested decision, to order the withdrawal of marketing authorisations for medicinal products containing amfepramone when it is not apparent from any new scientific information that the measures taken in the 1996 decision did not enable the objective pursued to be achieved.

82 It is to be observed that those arguments mainly concern the way in which the Commission exercised the discretion available to it when assessing the need for a measure withdrawing a marketing authorisation. It is not in dispute that any decision withdrawing a marketing authorisation which is adopted in accordance with the procedure laid down in Articles 13 and 14 of Directive 75/319 must comply with the substantive conditions under Article 11 of Directive 65/65, which relate to the efficacy, safety and quality of the medicinal product. This type of decision is thus the outcome of complex assessments in the medico-pharmacological field.

83 In principle, such assessments are subject to limited judicial review. According to the Court's case-law, where a Community authority is called upon, in the performance of its duties, to make complex assessments, it enjoys a wide measure of discretion, the exercise of which is subject to a limited judicial review in the course of which the Community judicature may not substitute its assessment of the facts for the assessment made by the authority concerned. Thus, in such cases, the Community judicature must restrict itself to examining the accuracy of the findings of fact and law made by the authority concerned and to verifying, in particular, that the action taken by that authority is not vitiated by a manifest error or a misuse of powers and that it did not clearly exceed the bounds of its discretion (see, with regard to withdrawal of a marketing authorisation for a medicinal product, Upjohn, cited above, paragraph 34).

84 In the present case, it does not appear, prima facie, that the contested decision, which is founded on the CPMP's opinion, is vitiated by a manifest error or a misuse of powers or that the Commission clearly exceeded the bounds of its discretion.

85 In addition, if the substantive conditions laid down in Article 11 of Directive 65/65 for withdrawal by the competent authorities of a marketing authorisation are met, it does not appear, on an initial analysis, that such a withdrawal is disproportionate or contrary to the principle of legal certainty.

86 Third, Trenker submits that the contested decision was adopted in breach of Directive 75/318, as amended by Commission Directive 1999/83/EC of 8 September 1999 (OJ 1999 L 243, p. 9). According to Trenker, where a medicinal product has enjoyed a marketing authorisation for a period of at least 10 years, as is the case with the medicinal products which it sells, it is presumed that the medicinal product's constituents have a well-established medicinal use and that the product offers an acceptable level of safety as well as recognised efficacy and, consequently, such a medicinal product cannot be assessed in the light of new evaluation criteria.

87 As to that, according to the annex to Directive 75/318, as amended by Directive 1999/83, the period of time of one decade from the first systematic and documented use of [the] substance as a medicinal product in the EU is only one condition, amongst many, for applying for marketing authorisation under the shortened procedure. Prima facie, the mere fact that a medicinal product has enjoyed a marketing authorisation for more than 10 years cannot be sufficient to prevent the competent authorities from suspending or withdrawing the authorisation where the conditions laid down in Article 11 of Directive 65/65 are met.

88 Fourth, Trenker contends that the obligation to state reasons set out in Article 253 EC has been infringed.

89 In that regard, it must be stated that the elements of the CPMP's opinion, which the Commission adopted by reproducing them in Annex II to the contested decision, prima facie contain a sufficient explanation of the reasons which led the Commission to decide to withdraw the marketing authorisations for medicinal products containing amfepramone.

90 Accordingly, without prejudice to the examination which will have to be carried out by the court dealing with the merits of the case, it must be concluded that the statement of reasons for the contested decision does not, prima facie, appear to be defective.

91 Finally, Trenker submits that it was only at the appeal stage, that is to say in response to the opinion issued by the CPMP on 22 April 1999, that it was heard by the CPMP with regard to the efficacy of medicinal products containing amfepramone. It follows that the contested decision was taken in breach of the general legal principle requiring the administration to hear interested parties fully before a decision liable to affect their interests seriously is adopted.

92 In that regard, it is apparent from the documents annexed by Trenker to its application for interim relief that it was requested to provide data on the efficacy of its medicinal products at the beginning of the procedure and that it submitted oral observations to the CPMP, concerning specifically the efficacy and the benefit/risk balance of medicinal products containing amfepramone, before that committee issued its first opinion. It was also able to comment on that opinion and thus to put forward its point of view before the CPMP adopted its final opinion.

93 In those circumstances, Trenker's arguments do not succeed in establishing, on an initial analysis, that its rights of defence were prejudiced.

94 It follows from the foregoing considerations that, without prejudice to the assessments to be made when the substance of the case is examined, the pleas put forward by Trenker in connection with the application for interim relief do not succeed, on an initial examination, in rebutting the presumption that the contested decision is valid.

95 Nevertheless, inasmuch as the pleas relied on by Trenker do not appear to be entirely without foundation, the interim relief sought cannot be refused after examination of whether a prima facie case is established without also examining the urgency that is pleaded and the balance of the competing interests.

Urgency and balancing of interests

96 Trenker submits that if operation of the contested decision is not suspended it will suffer serious and irreparable damage.

97 Withdrawal of the marketing authorisations for the medicinal products containing amfepramone would mean the exclusion of those products from the pharmaceutical trade lists and their removal from the lists of medicinal products used by the medical profession as a basis for advice and prescription practice. After such an extensive and lengthy withdrawal of those medicinal products from the market, when users would probably replace them with substitute products, the resumption of their marketing would be practically destined to fail. The confidence placed in them by consumers, doctors and pharmacists would be undermined once and for all.

98 Trenker adds that withdrawal of the marketing authorisations would destroy such a large part of its business that its existence would be threatened.

99 It is settled case-law that the urgency of an application for suspension of the operation of a measure must be assessed in the light of the need for an interlocutory order in order to avoid serious and irreparable damage to the party seeking the suspension. In this connection, it is enough, particularly where damage depends on the occurrence of a number of factors, for that damage to be foreseeable with a sufficient degree of probability (see, for example, the orders in Case C-280/93 R Germany v Council [1993] ECR I-3667, paragraphs 22 and 34, and in Case C-335/99 P(R) HFB and Others v Commission [1999] ECR I-8705, paragraph 67).

100 In the present case, immediate operation of the contested decision means the complete withdrawal from the market of the medicinal products referred to in Article 1 of the decision. Therefore, if operation of the contested decision is not suspended, it is probable that substitute medicinal products, whose existence is acknowledged by the parties, will be prescribed instead of the withdrawn medicinal products while the proceedings on the merits of the case take place.

101 The risk therefore exists that, if the contested decision is annulled, it will then be difficult for Trenker to recover the market shares which it held before the contested decision came into operation.

102 However, Trenker merely pleads difficulties in recovering market shares, in particular because there may be a loss of confidence in the medicinal products in question, and has not demonstrated at all that obstacles of a structural or legal nature would prevent doctors from prescribing such medicinal products again and it from regaining a significant proportion of those market shares following the putting into place, in particular, of appropriate publicity measures for doctors.

103 Trenker also submits that the contested decision jeopardises its survival because medicinal products containing amfepramone account for 30% of its overall turnover. A report drawn up at its request by a company auditor concludes that cessation of the delivery in Belgium of amfepramone-based medicinal products would inevitably jeopardise the company's survival.

104 However, the report is founded on the expectation that the sale of medicinal products containing amfepramone would cease from 1 July 1999 and that there would be no sales of those products in 2000 and 2001. That expectation did not materialise. Trenker itself acknowledges in its application for interim relief, lodged on 11 September 2000, that the medicinal products sold by [Trenker] are still on the market in Belgium.

105 Account should also be taken of the fact that Trenker operates in a market, the human medicinal products market, which is highly regulated.

106 In a sector where major investment is often required and the competent authorities may be led to intervene rapidly when public health risks become apparent, for reasons which cannot always be foreseen by the undertakings concerned, it is for those undertakings, if they are not to bear themselves the loss resulting from such intervention, to protect themselves against its consequences by adopting an appropriate policy.

107 It was already pointed out in the decision of 9 December 1996, which, moreover, was not challenged by Trenker, that medicinal products containing amfepramone had harmful effects. In those circumstances, the possibility that a decision could be adopted withdrawing or suspending the marketing authorisations held by Trenker had to be taken into account as one of the risks which Trenker normally had to bear once a referral had been made to the CPMP by a Member State because it considered that variation of the terms of the marketing authorisations or their suspension or withdrawal was necessary to protect public health.

108 In any event, even if the risk that damage which is irreparable or reparable only with difficulty would, following application of the contested decision, be suffered while the proceedings on the substance of the case take place were regarded as satisfactorily established, Trenker's interest in obtaining suspension of the operation of the contested decision could not prevail in the present case over the interest of the Community in the immediate withdrawal of the marketing authorisations held by it, with a view to protecting public health.

109 It must be remembered that, in principle, the requirements of the protection of public health must unquestionably be given precedence over economic considerations (order in United Kingdom v Commission, cited above, paragraph 93).

110 In the present case, it is not in dispute that the CPMP's opinion, to which the contested decision refers, pointed out, as regards effects on the central nervous system, that the medicinal products in question have serious effects such as psychotic reactions or psychosis, depression and convulsions and that the potential for drug abuse and drug dependence is well known. It also found that there were concerns related to the safety profile of [medicinal products containing amfepramone] concerning the risk of primary pulmonary hypertension and other serious cardiovascular ... adverse reactions .... Those considerations bear out the assessments already made on the safety of those medicinal products in 1996.

111 It was following the CPMP's assessments that medicinal products containing amfepramone lacked therapeutic efficacy in the treatment of obesity that the Commission, relying on the opinion of that committee, concluded that the benefit/risk assessment was unfavourable.

112 Without prejudice to the assessments to be made in the proceedings on the substance of the case, the judge hearing the application for interim relief cannot, in the absence of evidence of manifest error or misuse of powers, substitute his own assessments for those of the CPMP, which are the result of an in-depth inter partes procedure which led it to recommend the withdrawal of the marketing authorisations for medicinal products containing amfepramone.

113 Having regard to those assessments, it is evident that suspending the operation of the contested decision would be liable to make the users of those medicinal products run serious risks and, in terms of public health, would risk causing harm which could not be remedied if the substantive action were subsequently dismissed.

114 It follows from all the foregoing considerations that the application for interim relief must be dismissed.

Operative part

On those grounds,

THE PRESIDENT OF THE COURT

hereby orders:

1. The order of the President of the Court of First Instance of the European Communities of 19 October 2000 in Case T-141/00 R Trenker v Commission is set aside.

2. The application for interim relief is dismissed.

3. Costs are reserved.